Cargando…

Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease

INTRODUCTION: Evidence suggests that vascular inflammation and thrombosis may be important drivers of poor clinical outcomes in patients with COVID-19. We hypothesised that a significant decrease in the percentage of blood volume in vessels with a cross-sectional area between 1.25 and 5 mm(2) relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, Michael F., Pershad, Yash, Kang, Paul, Ridenour, Lauren, Lavon, Ben, Lanclus, Maarten, Godon, Rik, De Backer, Jan, Glassberg, Marilyn K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908189/
https://www.ncbi.nlm.nih.gov/pubmed/33632795
http://dx.doi.org/10.1183/13993003.04133-2020
_version_ 1783655655139180544
author Morris, Michael F.
Pershad, Yash
Kang, Paul
Ridenour, Lauren
Lavon, Ben
Lanclus, Maarten
Godon, Rik
De Backer, Jan
Glassberg, Marilyn K.
author_facet Morris, Michael F.
Pershad, Yash
Kang, Paul
Ridenour, Lauren
Lavon, Ben
Lanclus, Maarten
Godon, Rik
De Backer, Jan
Glassberg, Marilyn K.
author_sort Morris, Michael F.
collection PubMed
description INTRODUCTION: Evidence suggests that vascular inflammation and thrombosis may be important drivers of poor clinical outcomes in patients with COVID-19. We hypothesised that a significant decrease in the percentage of blood volume in vessels with a cross-sectional area between 1.25 and 5 mm(2) relative to the total pulmonary blood volume (BV5%) on chest computed tomography (CT) in COVID-19 patients is predictive of adverse clinical outcomes. METHODS: We performed a retrospective analysis of chest CT scans from 10 hospitals across two US states in 313 COVID-19-positive and 195 COVID-19-negative patients seeking acute medical care. RESULTS: BV5% was predictive of outcomes in COVID-19 patients in a multivariate model, with a BV5% threshold below 25% associated with OR 5.58 for mortality, OR 3.20 for intubation and OR 2.54 for the composite of mortality or intubation. A model using age and BV5% had an area under the receiver operating characteristic curve of 0.85 to predict the composite of mortality or intubation in COVID-19 patients. BV5% was not predictive of clinical outcomes in patients without COVID-19. CONCLUSIONS: The data suggest BV5% as a novel biomarker for predicting adverse outcomes in patients with COVID-19 seeking acute medical care.
format Online
Article
Text
id pubmed-7908189
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-79081892021-02-26 Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease Morris, Michael F. Pershad, Yash Kang, Paul Ridenour, Lauren Lavon, Ben Lanclus, Maarten Godon, Rik De Backer, Jan Glassberg, Marilyn K. Eur Respir J Original Research Articles INTRODUCTION: Evidence suggests that vascular inflammation and thrombosis may be important drivers of poor clinical outcomes in patients with COVID-19. We hypothesised that a significant decrease in the percentage of blood volume in vessels with a cross-sectional area between 1.25 and 5 mm(2) relative to the total pulmonary blood volume (BV5%) on chest computed tomography (CT) in COVID-19 patients is predictive of adverse clinical outcomes. METHODS: We performed a retrospective analysis of chest CT scans from 10 hospitals across two US states in 313 COVID-19-positive and 195 COVID-19-negative patients seeking acute medical care. RESULTS: BV5% was predictive of outcomes in COVID-19 patients in a multivariate model, with a BV5% threshold below 25% associated with OR 5.58 for mortality, OR 3.20 for intubation and OR 2.54 for the composite of mortality or intubation. A model using age and BV5% had an area under the receiver operating characteristic curve of 0.85 to predict the composite of mortality or intubation in COVID-19 patients. BV5% was not predictive of clinical outcomes in patients without COVID-19. CONCLUSIONS: The data suggest BV5% as a novel biomarker for predicting adverse outcomes in patients with COVID-19 seeking acute medical care. European Respiratory Society 2021-09-16 /pmc/articles/PMC7908189/ /pubmed/33632795 http://dx.doi.org/10.1183/13993003.04133-2020 Text en Copyright ©The authors 2021. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Original Research Articles
Morris, Michael F.
Pershad, Yash
Kang, Paul
Ridenour, Lauren
Lavon, Ben
Lanclus, Maarten
Godon, Rik
De Backer, Jan
Glassberg, Marilyn K.
Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease
title Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease
title_full Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease
title_fullStr Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease
title_full_unstemmed Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease
title_short Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease
title_sort altered pulmonary blood volume distribution as a biomarker for predicting outcomes in covid-19 disease
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908189/
https://www.ncbi.nlm.nih.gov/pubmed/33632795
http://dx.doi.org/10.1183/13993003.04133-2020
work_keys_str_mv AT morrismichaelf alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease
AT pershadyash alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease
AT kangpaul alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease
AT ridenourlauren alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease
AT lavonben alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease
AT lanclusmaarten alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease
AT godonrik alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease
AT debackerjan alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease
AT glassbergmarilynk alteredpulmonarybloodvolumedistributionasabiomarkerforpredictingoutcomesincovid19disease